Premier Biotech Acquires NexScreen and TransMed
June 19, 2026
Premier Biotech (backed by Align Capital Partners) announced the acquisitions of NexScreen and TransMed to expand its drug and alcohol testing diagnostic product portfolio and global footprint. The deals add NexScreen’s point-of-care diagnostic testing presence in Australia and New Zealand and TransMed’s drug testing product catalog, e-commerce platform, and direct customer base.
- Targets
- NexScreen, TransMed
- Platforms
- Premier Biotech
- Industry
- Healthcare Services
- Location
- Ohio, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.